Conditions: Lymphoma Cancer
Keywords: rollover protocol romidepsin Gloucester Pharmaceuticals Celgene Corporation continuing treatment
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.

Detailed description:
Participants must have previously participated in a Romidepsin study sponsored by Gloucester Pharmaceuticals or Celgene Corporation.

Arms:
arm 1: This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.

Interventions: intervention 1: Romidepsin
Intervention descriptions: intervention 1: The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.

Protocol document: